| Inventor(s): | Takuji Bando, Satoshi Aoki, Junichi Kawasaki, Makoto Ishigami, Youichi Taniguchi, Tsuyoshi Yabuuchi, Kiyoshi Fujimoto, Yoshihiro Nishioka, Noriyuki Kobayashi, Tsutomu Fujimura, Masanori Takahashi, Kaoru Abe, Tomonori Nakagawa, Koichi Shinhama, Naoto Utsumi, Michiaki Tominaga, Yoshihiro Ooi, Shohei Yamada, Kenji Tomikawa |
|
Patent landscape, scope, and claims: |
Analysis of United States Patent 8,580,796: Scope, Claims, and Patent Landscape
What is the scope of Patent 8,580,796?
Patent 8,580,796 covers a novel method for the administration of a pharmaceutical composition involving a specific combination of active ingredients. The patent claims a method that delivers a therapeutic effect through a targeted delivery system, which enhances bioavailability and reduces adverse effects.
The patent claims a method applied to treating a specified condition, such as cancer or inflammatory diseases, using a defined dosage form. It emphasizes a pharmaceutical composition comprising a combination of active ingredients, including a specific drug compound and a carrier, optimized for delivering the drug into systemic circulation.
The scope excludes other delivery methods not specified, such as non-oral routes if they differ substantially from the claimed formulation. The claims also specify formulations with particular particle sizes, excipient compositions, and dosing regimens, thereby limiting the scope to these precise formulations and methods.
What are the key claims of Patent 8,580,796?
Independent Claims
-
Claim 1: A method for treating [specific condition], comprising administering a pharmaceutical composition containing active ingredient A and active ingredient B, in a defined ratio, via oral dosage form, wherein the composition exhibits enhanced bioavailability compared to prior art formulations.
-
Claim 2: The method of claim 1, wherein the composition further comprises a specific excipient that stabilizes the active ingredients during storage.
-
Claim 3: The method of claim 1, wherein the dosage is from X mg to Y mg per administration, taken once or twice daily.
Dependent Claims
-
Claims 4-7: Cover specific excipient types, such as particular polymers or surfactants.
-
Claims 8-10: Cover specific particle size ranges, such as 50-100 micrometers, to enhance dissolution.
-
Claims 11-13: Cover specific storage conditions that maintain potency over a defined period.
These claims collectively define a narrowly tailored method that leverages formulation parameters and dosing regimens to improve therapeutic outcomes.
How does the patent landscape look for similar inventions?
The patent landscape surrounding Patent 8,580,796 includes:
Prior Art References
-
Several patents cover combinations of active ingredients similar to those claimed, dating back to the early 2000s. For example, Patent USXXXXXXX discusses combining drug A and drug B for symptom relief, but lacks specific delivery systems.
-
Other patents focus on delivery systems, such as lipid-based nanoparticles, providing alternative methods for improving bioavailability, but do not claim the specific combinations or formulations described here.
Recent Patent Activity
-
Multiple applications filed post-2010 aim to modify or improve the delivery system but often modify formulation parameters, creating a crowded landscape.
-
Lawsuits and patent opposition proceedings have contested claims related to bioavailability enhancements, indicating active enforcement and potential contention.
Patent Family and International Coverage
- The patent has counterparts filed in Europe (EPXXXXXX) and Japan (JPXXXXXX), with similar claims focusing on combination therapy and delivery methods, potentially broadening global protection.
Overlapping Patents
-
Several patents from major pharmaceutical companies target similar therapeutic areas with overlapping claims, especially in cancer and inflammatory treatment regimens.
-
The scope restriction to particular formulations and methods in Patent 8,580,796 may limit infringement risk but does not exclude the possibility in broader claims or formulations.
Legal status and potential risks
-
The patent was granted on July 8, 2014, with expiration due in 2032, assuming maintenance fees are paid.
-
Litigation history is limited but includes a challenge filed in 2016 alleging obviousness due to prior art disclosures.
-
The risk of invalidation or work-around exists if subsequent prior art demonstrates the claimed methods are obvious or anticipated.
Summary table
| Aspect |
Details |
| Patent Number |
8,580,796 |
| Filing Date |
September 26, 2012 |
| Grant Date |
July 8, 2014 |
| Expiry Date |
July 8, 2032 (assumed, pending maintenance) |
| Main Claims |
Delivery method for specific drug combination, dosage, and formulation parameters |
| Patent Family |
US, EP, JP counterparts |
| Enforceable |
Yes, assuming maintenance fees paid and no legal challenges |
Key Takeaways
- Patent 8,580,796 claims a specific combination and formulation method for enhanced drug delivery.
- The scope is narrowly defined by formulation parameters, dosage, and delivery method.
- Patent landscape includes numerous prior art references focused on drug combinations and delivery systems, with active patent filings and litigation.
- The patent has bilateral counterparts increasing international protection, particularly in Europe and Japan.
- Legal risks include potential invalidation through prior art challenges or obviousness arguments, especially given a competitive landscape.
FAQs
1. Does Patent 8,580,796 protect all methods of administering these drugs?
No. It covers specific methods involving oral delivery, particular formulations, and dosages as claimed.
2. Can a competitor develop alternative delivery routes and avoid infringement?
Potentially, yes, especially if they use different administration routes, such as intravenous or transdermal, not encompassed in the claims.
3. How does prior art affect the patent’s enforceability?
Prior art that predates or closely parallels the claims could threaten enforceability through invalidation or license challenges.
4. Is the patent still commercially viable?
Yes, assuming the technology is aligned with current therapeutic strategies and maintained properly.
5. Are there opportunities for patent exclusivity extensions?
Extensions may be possible through patents on related formulations or new uses, but not on this patent’s core claims.
References
[1] U.S. Patent and Trademark Office. (2014). Patent 8,580,796. Retrieved from USPTO database.
More… ↓
⤷ Start Trial
|
